Clinical and economic outcomes of an ambulatory urinary tract infection disease management program

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To evaluate the effectiveness of a urinary tract infection disease management program. Study design: A pre-post design was used. One year of data before and after promoting the treatment guideline were compared. Participants and methods: A 300,000-member managed care organization introduced an antibiotic treatment guideline designed to change the antibiotic prescribing practices of community physicians. The study intervention was the promotion of a treatment guideline through mailings and face-to-face interventions by 2 disease management specialists. A relational database was created to measure changes in health-care resources, use of antibiotics, and health event profiles. Results: The study demonstrated that prescribing patterns could be modified through treatment guideline distribution and face-to-face discussions. The study also found similar success rates across a range of antibiotics. Average health event costs decreased by 36% for kidney infections (P = .696) and by 7% for bladder infections (P < .05) after the treatment guideline was implemented; however, when controlling for patient age, sex, and comorbidities, the econometric model did not find a reduction in health event costs for either kidney or bladder infections. Fluoroquinolones were a cost driver compared with other antibiotics used to treat kidney and bladder infections. Conclusions: Considerations should be given to expanding the number of well-established antibiotics on the treatment guideline. Also, fluoroquinolones should be reserved for patients with sulfa allergies or failures with initial antibiotic treatment. In addition, it is recommended that future costs and outcomes be assessed after changes are made to the treatment guideline.

Original languageEnglish (US)
Pages (from-to)269-280
Number of pages12
JournalAmerican Journal of Managed Care
Volume7
Issue number3
StatePublished - 2001

Fingerprint

Urologic Diseases
Disease Management
Urinary Tract Infections
Economics
Disease
Guidelines
Anti-Bacterial Agents
costs
management
economics
event
health
allergy
Urinary Bladder
Fluoroquinolones
comorbidity
Therapeutics
Infection
Kidney
managed care

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine(all)
  • Health(social science)
  • Health Professions(all)

Cite this

@article{cae4f7c77d5a4c3a9ec407ba630fceef,
title = "Clinical and economic outcomes of an ambulatory urinary tract infection disease management program",
abstract = "Objective: To evaluate the effectiveness of a urinary tract infection disease management program. Study design: A pre-post design was used. One year of data before and after promoting the treatment guideline were compared. Participants and methods: A 300,000-member managed care organization introduced an antibiotic treatment guideline designed to change the antibiotic prescribing practices of community physicians. The study intervention was the promotion of a treatment guideline through mailings and face-to-face interventions by 2 disease management specialists. A relational database was created to measure changes in health-care resources, use of antibiotics, and health event profiles. Results: The study demonstrated that prescribing patterns could be modified through treatment guideline distribution and face-to-face discussions. The study also found similar success rates across a range of antibiotics. Average health event costs decreased by 36{\%} for kidney infections (P = .696) and by 7{\%} for bladder infections (P < .05) after the treatment guideline was implemented; however, when controlling for patient age, sex, and comorbidities, the econometric model did not find a reduction in health event costs for either kidney or bladder infections. Fluoroquinolones were a cost driver compared with other antibiotics used to treat kidney and bladder infections. Conclusions: Considerations should be given to expanding the number of well-established antibiotics on the treatment guideline. Also, fluoroquinolones should be reserved for patients with sulfa allergies or failures with initial antibiotic treatment. In addition, it is recommended that future costs and outcomes be assessed after changes are made to the treatment guideline.",
author = "Armstrong, {Edward P}",
year = "2001",
language = "English (US)",
volume = "7",
pages = "269--280",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "3",

}

TY - JOUR

T1 - Clinical and economic outcomes of an ambulatory urinary tract infection disease management program

AU - Armstrong, Edward P

PY - 2001

Y1 - 2001

N2 - Objective: To evaluate the effectiveness of a urinary tract infection disease management program. Study design: A pre-post design was used. One year of data before and after promoting the treatment guideline were compared. Participants and methods: A 300,000-member managed care organization introduced an antibiotic treatment guideline designed to change the antibiotic prescribing practices of community physicians. The study intervention was the promotion of a treatment guideline through mailings and face-to-face interventions by 2 disease management specialists. A relational database was created to measure changes in health-care resources, use of antibiotics, and health event profiles. Results: The study demonstrated that prescribing patterns could be modified through treatment guideline distribution and face-to-face discussions. The study also found similar success rates across a range of antibiotics. Average health event costs decreased by 36% for kidney infections (P = .696) and by 7% for bladder infections (P < .05) after the treatment guideline was implemented; however, when controlling for patient age, sex, and comorbidities, the econometric model did not find a reduction in health event costs for either kidney or bladder infections. Fluoroquinolones were a cost driver compared with other antibiotics used to treat kidney and bladder infections. Conclusions: Considerations should be given to expanding the number of well-established antibiotics on the treatment guideline. Also, fluoroquinolones should be reserved for patients with sulfa allergies or failures with initial antibiotic treatment. In addition, it is recommended that future costs and outcomes be assessed after changes are made to the treatment guideline.

AB - Objective: To evaluate the effectiveness of a urinary tract infection disease management program. Study design: A pre-post design was used. One year of data before and after promoting the treatment guideline were compared. Participants and methods: A 300,000-member managed care organization introduced an antibiotic treatment guideline designed to change the antibiotic prescribing practices of community physicians. The study intervention was the promotion of a treatment guideline through mailings and face-to-face interventions by 2 disease management specialists. A relational database was created to measure changes in health-care resources, use of antibiotics, and health event profiles. Results: The study demonstrated that prescribing patterns could be modified through treatment guideline distribution and face-to-face discussions. The study also found similar success rates across a range of antibiotics. Average health event costs decreased by 36% for kidney infections (P = .696) and by 7% for bladder infections (P < .05) after the treatment guideline was implemented; however, when controlling for patient age, sex, and comorbidities, the econometric model did not find a reduction in health event costs for either kidney or bladder infections. Fluoroquinolones were a cost driver compared with other antibiotics used to treat kidney and bladder infections. Conclusions: Considerations should be given to expanding the number of well-established antibiotics on the treatment guideline. Also, fluoroquinolones should be reserved for patients with sulfa allergies or failures with initial antibiotic treatment. In addition, it is recommended that future costs and outcomes be assessed after changes are made to the treatment guideline.

UR - http://www.scopus.com/inward/record.url?scp=0035082511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035082511&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 269

EP - 280

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 3

ER -